Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping

[1]  T. Crawford,et al.  Early treatment is a lifeline for infants with SMA , 2022, Nature Medicine.

[2]  C. Gerrits,et al.  Delays in pulmonary decline in eteplirsen‐treated patients with Duchenne muscular dystrophy , 2022, Muscle & nerve.

[3]  R. Finkel,et al.  Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial , 2022, Nature Medicine.

[4]  Norah L. Crossnohere,et al.  Duchenne expert physician perspectives on Duchenne newborn screening and early Duchenne care , 2022, American journal of medical genetics. Part C, Seminars in medical genetics.

[5]  Y. Chien,et al.  Duchenne muscular dystrophy newborn screening: the first 50,000 newborns screened in Taiwan , 2022, Neurological Sciences.

[6]  K. Mathews,et al.  Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000‐2015 , 2022, Muscle & nerve.

[7]  G. Comi,et al.  Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial , 2022, The Lancet Neurology.

[8]  V. Ricotti,et al.  Genotype‐related respiratory progression in Duchenne muscular dystrophy—A multicenter international study , 2021, Muscle & nerve.

[9]  B. Byrne,et al.  A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment , 2021, Journal of neuromuscular diseases.

[10]  E. Bertini,et al.  North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up , 2021, PloS one.

[11]  J. Mendell,et al.  Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial , 2021, Journal of neuromuscular diseases.

[12]  P. Shieh,et al.  Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trial , 2021, Muscle & nerve.

[13]  L. Servais,et al.  Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy , 2021, Scientific Reports.

[14]  J. Mendell,et al.  Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls , 2021, Journal of neuromuscular diseases.

[15]  J. Mendell,et al.  Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. , 2020, Pediatric neurology.

[16]  P. van Dommelen,et al.  Early developmental milestones in Duchenne muscular dystrophy , 2020, Developmental medicine and child neurology.

[17]  A. Blaschek,et al.  Qualitative and quantitative muscle ultrasound in patients with Duchenne muscular dystrophy: Where do sonographic changes begin? , 2020, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  R. Raina,et al.  Challenges of Vascular Access in the Pediatric Population. , 2020, Advances in chronic kidney disease.

[19]  E. Mercuri,et al.  Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy , 2020, Neurology.

[20]  G. Oudit,et al.  Cardiac Intervention Improves Heart Disease and Clinical Outcomes in Patients With Muscular Dystrophy in a Multidisciplinary Care Setting , 2020, Journal of the American Heart Association.

[21]  E. Bertini,et al.  Longitudinal natural history in young boys with Duchenne muscular dystrophy , 2019, Neuromuscular Disorders.

[22]  R. Finkel,et al.  Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study , 2019, Neuromuscular Disorders.

[23]  G. Comi,et al.  Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53 , 2019, PloS one.

[24]  J. Mendell,et al.  Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy , 2019, Medicine.

[25]  R. Finkel,et al.  Twice‐weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy , 2019, Muscle & nerve.

[26]  R. Griggs,et al.  Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy , 2019, World Journal of Pediatrics.

[27]  S. Bhalla,et al.  Tolerability of Eteplirsen for Duchenne Muscular Dystrophy in the Youngest Reported Patient Treated With This Therapy (P2.332) , 2018, Neurology.

[28]  S. Pandya,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management , 2018, The Lancet Neurology.

[29]  R. Finkel,et al.  Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[30]  J. Mendell,et al.  Clinical Follow‐Up for Duchenne Muscular Dystrophy Newborn Screening: A Proposal , 2016, Muscle & nerve.

[31]  B. Byrne,et al.  Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy , 2015, Annals of neurology.

[32]  P. Smith,et al.  Pharmacokinetic studies in infants using minimal-risk study designs. , 2014, Current clinical pharmacology.

[33]  G. Comi,et al.  Ataluren treatment of patients with nonsense mutation dystrophinopathy , 2014, Muscle & nerve.

[34]  K. Bushby,et al.  Improving recognition of Duchenne muscular dystrophy: a retrospective case note review , 2014, Archives of Disease in Childhood.

[35]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[36]  Y. Chien,et al.  Pompe disease: early diagnosis and early treatment make a difference. , 2013, Pediatrics and neonatology.

[37]  G. Comi,et al.  24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy , 2013, PloS one.

[38]  R. Schleip,et al.  The role of fibrosis in Duchenne muscular dystrophy , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[39]  G. Piluso,et al.  Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients , 2012, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[40]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[41]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[42]  J. Bach,et al.  The respiratory management of patients with duchenne muscular dystrophy: A DMD care considerations working group specialty article , 2010, Pediatric pulmonology.

[43]  S. Pandya,et al.  Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). , 2009, The Journal of pediatrics.

[44]  I. Graham,et al.  Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Y. W. Chen,et al.  Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy , 2005, Neurology.

[46]  Kevin V Lemley,et al.  National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. , 2003, Pediatrics.

[47]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[48]  J. Rapola,et al.  Isolated proteinuria: analysis of a school-age population. , 1982, The Journal of pediatrics.

[49]  W. Bradley,et al.  Structural changes in the early stages of Duchenne muscular dystrophy , 1972, Journal of neurology, neurosurgery, and psychiatry.